Phase 3 Study to Evaluate Efficacy and Safety of NU100 in Patients With Relapsing Remitting Multiple Sclerosis (RRMS)

NCT01464905 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

500

Enrollment

INDUSTRY

Sponsor class

Conditions

Relapsing Remitting Multiple Sclerosis

Interventions

BIOLOGICAL: NU100
BIOLOGICAL: Placebo
BIOLOGICAL: rhIFN beta-1b

Sponsor

Nuron Biotech Inc.